S. Kane

发表

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

R. Spencer, L. Kiss, J. Culberson, 2009, Biochemical pharmacology.

Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis

C. Regan, J. Lynch, G. Stump, 2009, Journal of Pharmacology and Experimental Therapeutics.

Synthesis, structure-activity relationship, and pharmacological profile of analogs of the ASIC-3 inhibitor A-317567.

S. Kuduk, R. Spencer, A. Jovanovska, 2010, ACS chemical neuroscience.

Amiloride derived inhibitors of acid-sensing ion channel-3 (ASIC3).

M. Bock, R. M. Dipardo, S. Kuduk, 2009, Bioorganic & medicinal chemistry letters.

Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

W. S. Denney, B. Van der Schueren, T. Ho, 2010, British journal of clinical pharmacology.

Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3).

R. M. Dipardo, S. Kuduk, R. Spencer, 2011, Bioorganic & medicinal chemistry letters.

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

K. K. Nanda, C. Lindsley, R. Spencer, 2017, Bioorganic & medicinal chemistry letters.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

CGRP Receptor Antagonists for Migraine: Challenges and Promises

S. Kane, C. Salvatore, 2010 .

Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system.

Y. Shen, R. Gould, J. Lynch, 2001, The Journal of pharmacology and experimental therapeutics.

Effect of Calcitonin Gene-Related Peptide Receptor Antagonism on the Systemic Blood Pressure Responses to Mechanistically Diverse Vasomodulators in Conscious Rats

C. Regan, J. Lynch, S. Kane, 2010, Journal of cardiovascular pharmacology.

Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine.

H. Selnick, M. Fraley, D. Gauvreau, 2015, Bioorganic & medicinal chemistry letters.

Identification of a novel RAMP-independent CGRP receptor antagonist.

J. Vacca, S. Graham, R. Z. Rutledge, 2011, Bioorganic & medicinal chemistry letters.

Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding.

D. Hay, S. Kane, J. Gingell, 2010, Biochemical and biophysical research communications.

Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.

A. W. Shaw, Y. S. Tang, S. Kane, 2009, European journal of pharmacology.

Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

A. W. Shaw, J. Vacca, Victor K. Johnston, 2008, Journal of Pharmacology and Experimental Therapeutics.

Active CGRP Receptor Antagonist for the Treatment of Migraine

A. W. Shaw, J. Vacca, S. Graham, 2007 .

Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure.

R. Hargreaves, R. Gould, You-tang Shen, 2003, Journal of cardiovascular pharmacology.

Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries

R. Hargreaves, L. Edvinsson, J. Lynch, 2010, Journal of Pharmacology and Experimental Therapeutics.

Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists* 210

J. Longmore, K. Koblan, S. Kane, 2002, The Journal of Biological Chemistry.

CGRP receptor antagonists: toward a novel migraine therapy.

S. Kane, C. Salvatore, 2011, Current pharmaceutical biotechnology.

Effects of Inhibition of &agr;-CGRP Receptors on Cardiac and Peripheral Vascular Dynamics in Conscious Dogs with Chronic Heart Failure

R. Hargreaves, R. Gould, You-tang Shen, 2003 .

Characterization of the CGRP receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries

L. Edvinsson, R. Vries, R. Hargreaves, 2010 .

High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.

R. Spencer, L. Kiss, K. Koblan, 2009, Biochemical pharmacology.

High-throughput analysis of drug binding interactions for the human cardiac channel , Kv 1

R. Spencer, L. Kiss, K. Koblan, 2008 .

Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells.

R. Alm, L. Edvinsson, R. Z. Rutledge, 2002, European journal of pharmacology.

Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries.

J. Tajti, L. Edvinsson, I. Jansen-Olesen, 2001, European journal of pharmacology.

Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1−/− and not CB2−/− mice in models of acute and persistent pain

M. Urban, S. Kane, A. Liang, 2009, Neuropharmacology.

[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.

Sandra M. Sanabria-Bohórquez, L. Gantert, E. Hostetler, 2013, ACS medicinal chemistry letters.

Polynucleotide recognition and degradation by bleomycin.

S. Hecht, S. Kane, 1994, Progress in nucleic acid research and molecular biology.

Comparison of the Vasoconstrictor Effects of the Calcitonin Gene-related Peptide Receptor Antagonist Telcagepant (MK-0974) and Zolmitriptan in Human Isolated Coronary Arteries

R. Hargreaves, L. Edvinsson, C. Regan, 2010, Journal of cardiovascular pharmacology.

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

J. Vacca, H. Selnick, S. Graham, 2012, Bioorganic & medicinal chemistry letters.

Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.

A. W. Shaw, S. Graham, R. Z. Rutledge, 2007, Bioorganic & medicinal chemistry letters.

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.

J. Vacca, S. Graham, R. Z. Rutledge, 2006, Bioorganic & medicinal chemistry letters.

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).

A. W. Shaw, J. Vacca, Victor K. Johnston, 2007, Journal of medicinal chemistry.

Molecules d'adn isolees codant un recepteur humanise du peptide lie au gene de la calcitonine, animaux transgeniques non humains associes et methodes d'analyse

K. Koblan, S. Kane, K. Oliver, 2002 .

Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.

S. Lippard, S. Kane, Stefanie A. Kane, 1996, Biochemistry.

Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.

A. W. Shaw, J. Vacca, H. Selnick, 2011, Bioorganic & medicinal chemistry letters.

GUANOSINE-SPECIFIC DNA DAMAGE BY A CO(II).BITHIAZOLE COMPLEX

S. Hecht, H. Sasaki, S. Kane, 1995 .

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Kenneth D Anderson, K. K. Nanda, N. Liverton, 2006, Journal of medicinal chemistry.

Potent benzimidazolone-based CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2008, Bioorganic & medicinal chemistry letters.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

The discovery of highly potent CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.

Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

K. K. Nanda, D. Henze, Suzie Yeh, 2011, Bioorganic & medicinal chemistry letters.

Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence.

P. Huang, A. Musselman, S. Kane, 2000, Analytical biochemistry.

On the role of the bithiazole moiety in sequence-selective DNA cleavage by Fe.bleomycin.

S. Hecht, A. Natrajan, S. Kane, 1994, The Journal of biological chemistry.

Differential Distribution of Calcitonin Gene-related Peptide (cgrp) and Its Receptor Components in the Human Trigeminal Ganglion

J. Tajti, L. Edvinsson, S. Kane, 2022 .

HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity

D. Henze, M. Urban, S. R. Eid, 2008, Molecular pain.

Reversal of acid‐induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2

V. Garsky, R. Spencer, M. Urban, 2010, British journal of pharmacology.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

J. Vacca, P. Kunapuli, S. Graham, 2006, Bioorganic & medicinal chemistry letters.

In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

Sandra M. Sanabria-Bohórquez, G. Bormans, L. Gantert, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Calcitonin Gene-Related Peptide8-37 Antagonizes Capsaicin-Induced Vasodilation in the Skin: Evaluation of a Human in Vivo Pharmacodynamic Model

B. Van der Schueren, F. Vanmolkot, A. Rogiers, 2008, Journal of Pharmacology and Experimental Therapeutics.

In vitro characterization of novel NR2B selective NMDA receptor antagonists

L. Kiss, P. Bennett, J. Mccauley, 2005, Neurochemistry International.

Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat

R. Heavens, R. Hill, K. Koblan, 2001, The European journal of neuroscience.

High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors.

Zhijian Zhao, James C Barrow, Scott T. Harrison, 2011, Bioorganic & medicinal chemistry letters.

Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3).

R. M. Dipardo, S. Kuduk, R. Spencer, 2009, Bioorganic & medicinal chemistry letters.

Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

B. Van der Schueren, F. Vanmolkot, A. van Hecken, 2007, British journal of clinical pharmacology.

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

Kenneth D Anderson, C. Regan, R. Gould, 2009, European journal of pharmacology.

The Prototype Serotonin 5-HT1B/1D Agonist Sumatriptan Increases the Severity of Myocardial Ischemia During Atrial Pacing in Dogs With Coronary Artery Stenosis

C. Regan, J. Lynch, G. Stump, 2009, Journal of cardiovascular pharmacology.

Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.

K. K. Nanda, C. Lindsley, R. Spencer, 2006, Bioorganic & medicinal chemistry letters.

High throughput ion-channel pharmacology: planar-array-based voltage clamp.

Paul B Bennett, Kirk Schroeder, V. Uebele, 2003, Assay and drug development technologies.

Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.

J. Vacca, H. Selnick, I. M. Bell, 2009, Bioorganic & medicinal chemistry letters.

Inhibition of capsaicin-induced increase in dermal microvascular blood flow by the oral CGRP antagonist, MK-0974

J. Palcza, M. Murphy, N. Agrawal, 2007 .

Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay

R. Hargreaves, T. Williams, E. Baskin, 2005, Regulatory Peptides.

Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.

D. Henze, Suzie Yeh, G. Hartman, 2011, Bioorganic & medicinal chemistry letters.

Identification of potent, highly constrained CGRP receptor antagonists.

Steven S. Sharik, Cory R. Theberge, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

J. Vacca, C. Regan, T. Prueksaritanont, 2010, ACS medicinal chemistry letters.

The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

J. Tajti, L. Edvinsson, S. Kane, 2010, Neuroscience.

Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries

I. Garrelds, A. Maassenvandenbrink, S. Kane, 2010, Journal of Pharmacology and Experimental Therapeutics.

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.

J. Vacca, T. Williams, Sean Yu, 2009, Bioorganic & medicinal chemistry letters.

Synthesis, structure-activity relationship, and pharmacological profile of analogs of the ASIC-3 inhibitor A-317567.

S. Kuduk, R. Spencer, A. Jovanovska, 2010, ACS chemical neuroscience.

Reversal of acid‐induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2

V. Garsky, R. Spencer, M. Urban, 2010, British journal of pharmacology.